Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ: AVIR · Real-Time Price · USD

2.880

+0.010 (0.35%)

Apr 25, 2025, 12:02 PM EDT - Market open

Atea Pharmaceuticals Employees

Atea Pharmaceuticals had 56 employees as of December 31, 2024. The number of employees decreased by 19 or -25.33% compared to the previous year.

Employees

56

Change (1Y)

-19

Growth (1Y)

-25.33%

Revenue / Employee

n/a

Profits / Employee

-$3,006,875

Market Cap

246.31M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	56	-19	-25.33%
Dec 31, 2023	75	5	7.14%
Dec 31, 2022	70	11	18.64%
Dec 31, 2021	59	20	51.28%
Dec 31, 2020	39	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novartis AG	75,883

Employee Rankings

AVIR News

2 days ago - Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewsWire
8 days ago - Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewsWire
16 days ago - Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
24 days ago - Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - GlobeNewsWire
4 weeks ago - Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - GlobeNewsWire
4 weeks ago - The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
4 weeks ago - Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewsWire
5 weeks ago - Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 - GlobeNewsWire